SMYD2 and B-cell chronic lymphocytic leukemia: In line with our findings in AML, low levels of SMYD2 correlated with shorter survival in patients with renal cell carcinoma [69] and acquisition of complex karyotype and disease progression in chronic lymphocytic leukemia [70].